Bicycle Therapeutics Collaborated with German Cancer Research Center to Discover and Develop Bicycle Radio Conjugates for a Range of Oncology Targets
Shots:
- The purpose of the collaboration with Bicycle & German Cancer Research Center (DKFZ) is to develop a pipeline of wholly-owned BRC compounds with the potential to become new treatment options for cancer patients
- Tumor targeting BRCs showed a superior tumor uptake over Ab-based approaches in preclinical studies which were published in Cancer Research
- Multiple updates were reported in 2023 & advancing BT8009 (BTC targeting Nectin-4), BT5528 (BTC targeting EphA2) and BT7480 (TICA targeting Nectin-4 and agonizing CD137) in the clinic. BRCs’ initial testing is expected to be initiated for the patients at the end of 2024
Ref: Businesswire | Image: bicycle-therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
